Avian reovirus vaccines
AssigneeUniversity of Georgia Research Foundation, Inc.
InventorHolly S. Sellers
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses.
Claims20
An isolated avian reovirus, wherein the avian reovirus comprises
- a sigma C protein comprising an amino acid sequence with at least 98% sequence identity to SEQ ID NO:2 and comprising at least one amino acid difference from SEQ ID NO:2;
- wherein the avian reovirus is attenuated relative to an avian reovirus comprising a sigma C protein with an amino acid sequence comprising SEQ ID NO:2 by at least 25 passages in an egg or a host cell line.
An isolated avian reovirus, wherein the avian reovirus comprises the avian reovirus strain 94594 deposited at the ATCC under Patent Designation PTA-125687 attenuated by at least 125 passages in an egg or a host cell line.
Dependencies are inferred from the claim text.